Impact ledger
BioCardia, Inc. (BCDA): the developments shaping its investment case
Follow the evidence affecting BioCardia, Inc.'s valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-06-12 | multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. |
| 2026-06-12 | share_count | Bullish | Primary equity issuance increases diluted share count. |
Event impact log
2 events mapped to BCDA since 2026-09-23. Evidence through 2026-09-23.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-23 | BioCardia, Inc. Provides Update on FDA and PMDA Regulatory Submissions | Direct progress towards regulatory approval and commercialization for key product candidates. De-risking of clinical development. | Bullish | 1-3m | 0.80 |
| 2026-09-23 | BioCardia Confirms Timing for FDA Helix Pre-Submission and PMDA CardiAMP HF Submission | Direct regulatory progress for key product candidates (Helix system and CardiAMP HF) reduces development risk and signals potential market entry, which could increase investor confidence and future revenue expectations. | Bullish | 3-12m | 0.80 |
Continue this research
Build your BioCardia, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the BCDA entity page →